<unk> , sold under the brand name Bavencio, is a fully human monoclonal antibody medication for the treatment of Merkel cell carcinoma, urothelial carcinoma, and renal cell carcinoma. Common side effects include fatigue, musculoskeletal pain, diarrhea, nausea, infusion-related reactions, rash, decreased appetite and swelling of the limbs (peripheral edema).<unk>  targets the protein programmed death-ligand 1 (PD-L1). It has received orphan drug designation by the European Medicines Agency (EMA) for the treatment of gastric cancer in January 2017. The US Food and Drug Administration (FDA) approved it in March 2017 for Merkel-cell carcinoma. an aggressive type of skin cancer. The EMA approved it in September 2017 for the same indication. This is the first FDA-approved treatment for metastatic MCC, a rare, aggressive form of skin cancer.<unk>  was developed by Merck KGaA and Pfizer.
Avelumab
Alirocumab
Emapalumab
Anifrolumab
Burosumab
Evolocumab
Secukinumab
Olaratumab